B-intervention	0	10	Ultrasound
I-intervention	10	11	-
I-intervention	11	17	guided
I-intervention	18	26	serratus
I-intervention	27	32	plane
I-intervention	33	38	block
O	39	47	enhances
B-condition	48	52	pain
I-condition	53	59	relief
I-condition	60	63	and
I-condition	64	71	quality
I-condition	72	74	of
I-condition	75	83	recovery
O	84	89	after
O	90	96	breast
O	97	103	cancer
O	104	111	surgery
O	111	112	:
O	113	114	A
O	115	125	randomised
O	126	136	controlled
O	137	142	trial
O	142	143	.

O	144	154	Multimodal
O	155	164	analgesia
O	165	168	can
O	169	176	improve
O	177	190	postoperative
O	191	195	pain
O	196	199	and
O	200	208	possibly
O	209	219	accelerate
O	220	230	functional
O	231	239	recovery
O	240	245	after
O	246	253	surgery
O	253	254	.

O	255	263	Serratus
O	264	269	plane
O	270	275	block
O	276	277	(
O	277	280	SPB
O	280	281	)
O	282	284	is
O	285	286	a
O	287	292	novel
O	292	293	,
O	294	304	ultrasound
O	304	305	-
O	305	311	guided
O	312	320	regional
O	321	332	anaesthetic
O	333	342	technique
O	343	346	for
O	347	355	complete
O	356	365	analgesia
O	366	368	of
O	369	372	the
O	373	386	anterolateral
O	387	392	chest
O	393	397	wall
O	397	398	.

O	399	402	But
O	402	403	,
O	404	407	the
O	408	414	effect
O	415	417	of
O	418	421	SPB
O	422	424	on
O	425	428	the
O	429	436	quality
O	437	439	of
O	440	448	recovery
O	449	454	after
O	455	461	breast
O	462	468	cancer
O	469	476	surgery
O	477	480	has
O	481	484	not
O	485	489	been
O	490	501	established
O	501	502	.

O	503	505	To
O	506	510	test
O	511	514	the
O	515	525	hypothesis
O	526	530	that
O	531	534	pre
O	534	535	-
O	535	544	operative
O	545	548	SPB
O	549	554	would
O	555	562	enhance
O	563	566	the
O	567	574	quality
O	575	577	of
O	578	586	recovery
O	587	596	following
O	597	603	breast
O	604	610	cancer
O	611	618	surgery
O	618	619	.

O	620	621	A
O	622	632	randomised
O	632	633	,
O	634	640	double
O	640	641	-
O	641	646	blind
O	646	647	,
O	648	656	parallel
O	656	657	-
O	657	662	group
O	662	663	,
O	664	671	placebo
O	671	672	-
O	672	682	controlled
O	683	688	trial
O	688	689	.

O	690	696	Single
O	697	707	university
O	708	716	teaching
O	717	725	hospital
O	725	726	,
O	727	731	from
O	732	737	March
O	738	742	2016
O	743	745	to
O	746	750	June
O	751	755	2017
O	755	756	.

B-total-participants	757	764	Seventy
I-total-participants	764	765	-
I-total-participants	765	768	two
B-eligibility	769	774	women
I-eligibility	775	784	scheduled
I-eligibility	785	788	for
I-eligibility	789	795	breast
I-eligibility	796	802	cancer
I-eligibility	803	810	surgery
O	810	811	.

O	812	824	Participants
O	825	829	were
O	830	840	randomised
O	841	843	in
O	844	845	a
O	846	847	1
O	848	849	:
O	850	851	1
O	852	857	ratio
O	858	860	to
O	861	868	receive
O	869	872	SPB
O	873	877	with
O	878	880	25
O	881	883	ml
O	884	886	of
O	887	898	ropivacaine
O	899	900	0
O	900	901	.
O	901	902	5
O	902	903	%
O	904	906	or
B-control	907	920	physiological
I-control	921	927	saline
O	927	928	.

O	929	932	The
O	933	940	primary
O	941	949	endpoint
O	950	953	was
O	954	957	the
B-outcome-Measure	958	960	40
I-outcome-Measure	960	961	-
I-outcome-Measure	961	965	item
I-outcome-Measure	966	973	Quality
I-outcome-Measure	974	976	of
I-outcome-Measure	977	985	Recovery
I-outcome-Measure	986	999	questionnaire
I-outcome-Measure	1000	1005	score
I-outcome-Measure	1006	1008	24
I-outcome-Measure	1009	1014	hours
I-outcome-Measure	1015	1030	postoperatively
I-outcome-Measure	1031	1036	hours
O	1036	1037	.

O	1038	1047	Secondary
O	1048	1057	endpoints
O	1058	1062	were
B-outcome-Measure	1063	1076	postoperative
I-outcome-Measure	1077	1081	pain
I-outcome-Measure	1082	1091	intensity
O	1091	1092	,
B-outcome-Measure	1093	1103	cumulative
I-outcome-Measure	1104	1110	opioid
I-outcome-Measure	1111	1122	consumption
O	1122	1123	,
B-outcome-Measure	1124	1137	postoperative
I-outcome-Measure	1138	1144	nausea
I-outcome-Measure	1145	1148	and
I-outcome-Measure	1149	1157	vomiting
O	1157	1158	,
B-outcome-Measure	1159	1168	dizziness
O	1168	1169	,
B-outcome-Measure	1170	1174	post
I-outcome-Measure	1175	1186	anaesthesia
I-outcome-Measure	1187	1191	care
I-outcome-Measure	1192	1196	unit
I-outcome-Measure	1197	1206	discharge
I-outcome-Measure	1207	1211	time
O	1212	1215	and
B-outcome-Measure	1216	1223	patient
I-outcome-Measure	1224	1236	satisfaction
O	1236	1237	.

O	1238	1241	The
O	1242	1248	global
O	1249	1255	median
O	1256	1257	[
O	1257	1260	IQR
O	1260	1261	]
B-outcome	1262	1264	40
I-outcome	1264	1265	-
I-outcome	1265	1269	item
I-outcome	1270	1277	Quality
I-outcome	1278	1280	of
I-outcome	1281	1289	Recovery
I-outcome	1290	1303	questionnaire
I-outcome	1304	1309	score
O	1310	1312	at
O	1313	1315	24
O	1316	1329	postoperative
O	1330	1335	hours
O	1336	1339	was
O	1340	1353	significantly
O	1354	1360	higher
O	1361	1363	in
O	1364	1367	the
O	1368	1371	SPB
O	1372	1377	group
O	1378	1379	(
B-iv-cont-median	1379	1382	158
O	1383	1384	[
O	1384	1387	153
O	1387	1388	.
O	1388	1389	8
O	1390	1392	to
O	1393	1396	159
O	1396	1397	.
O	1397	1398	3
O	1398	1399	]
O	1399	1400	)
O	1401	1405	than
O	1406	1409	the
O	1410	1417	control
O	1418	1423	group
O	1424	1425	(
B-cv-cont-median	1425	1428	141
O	1429	1430	[
O	1430	1433	139
O	1434	1436	to
O	1437	1440	145
O	1440	1441	.
O	1441	1442	3
O	1442	1443	]
O	1443	1444	)
O	1445	1449	with
O	1450	1451	a
O	1452	1458	median
O	1459	1469	difference
O	1470	1472	of
O	1473	1475	15
O	1476	1477	(
O	1477	1479	95
O	1479	1480	%
O	1481	1491	confidence
O	1492	1500	interval
O	1500	1501	:
O	1502	1504	13
O	1505	1507	to
O	1508	1510	17
O	1510	1511	,
O	1512	1513	P
O	1514	1515	<
O	1516	1517	0
O	1517	1518	.
O	1518	1521	001
O	1521	1522	)
O	1522	1523	.

O	1524	1532	Compared
O	1533	1537	with
O	1538	1541	the
O	1542	1549	control
O	1550	1555	group
O	1555	1556	,
B-outcome	1557	1570	postoperative
I-outcome	1571	1575	pain
I-outcome	1576	1582	scores
O	1583	1585	at
O	1586	1590	rest
O	1591	1595	were
O	1596	1609	significantly
O	1610	1615	lower
O	1616	1618	up
O	1619	1621	to
O	1622	1624	24
O	1625	1626	h
O	1627	1629	in
O	1630	1633	the
O	1634	1637	SPB
O	1638	1643	group
O	1643	1644	.

O	1645	1648	Pre
O	1648	1649	-
O	1649	1658	operative
O	1659	1662	SPB
O	1663	1670	reduced
B-outcome	1671	1684	postoperative
I-outcome	1685	1695	cumulative
I-outcome	1696	1702	opioid
I-outcome	1703	1714	consumption
O	1714	1715	,
O	1716	1719	the
B-outcome	1720	1729	incidence
I-outcome	1730	1732	of
I-outcome	1733	1746	postoperative
I-outcome	1747	1753	nausea
I-outcome	1754	1757	and
I-outcome	1758	1766	vomiting
O	1767	1770	and
O	1771	1774	the
B-outcome	1775	1779	post
I-outcome	1780	1791	anaesthesia
I-outcome	1792	1796	care
I-outcome	1797	1801	unit
I-outcome	1802	1811	discharge
I-outcome	1812	1816	time
O	1816	1817	.

O	1818	1820	In
O	1821	1829	addition
O	1829	1830	,
B-outcome	1831	1838	patient
I-outcome	1839	1851	satisfaction
I-outcome	1852	1858	scores
O	1859	1863	were
O	1864	1870	higher
O	1871	1873	in
O	1874	1877	the
O	1878	1881	SPB
O	1882	1887	group
O	1887	1888	.

O	1889	1892	Pre
O	1892	1893	-
O	1893	1902	operative
O	1903	1917	administration
O	1918	1920	of
O	1921	1924	SPB
O	1925	1929	with
O	1930	1941	ropivacaine
O	1942	1950	improved
O	1951	1954	the
O	1955	1962	quality
O	1963	1965	of
O	1966	1974	recovery
O	1974	1975	,
O	1976	1989	postoperative
O	1990	1999	analgesia
O	2000	2003	and
O	2004	2011	patient
O	2012	2024	satisfaction
O	2025	2034	following
O	2035	2041	breast
O	2042	2048	cancer
O	2049	2056	surgery
O	2056	2057	.

O	2058	2072	ClinicalTrials
O	2072	2073	.
O	2073	2076	gov
O	2077	2078	(
O	2078	2088	identifier
O	2088	2089	:
O	2090	2101	NCT02691195
O	2101	2102	)
O	2102	2103	.
